STAA

Over the past six months, STAAR Surgical reported strong Q2 CY2026 results in August 2026, beating revenue and GAAP profit estimates with a 111% year-on-year revenue increase to $93.54 million and increased free cash flow. In September 2026, the company's board authorized a $50 million share repurchase program, which led to a 6.3% stock price jump. Later that month, Stifel upgraded STAAR Surgical from 'Hold' to 'Buy' and raised its price target, citing expected revenue growth in the second half of 2026 due to a favorable product mix and recovering Chinese market, causing the stock to jump 6.4% in pre-market trading. Also in September 2026, David Bailey was named Chief Commercial Officer and Ben Park was appointed Chief Technology Officer. Despite these positive events, the stock experienced a decrease of 5.62% in the past month and 17.44% over the last 12 months as of October 6, 2026.